Key facts
- GeneCentric’s last known valuation is $40.0M (Jun 2025).
- It has raised $28.1M; the latest was Later Stage VC ($8.0M) in Jun 2025.
- Notable investors include Alexandria Venture Investments, IAG Capital Partners, Labcorp Venture Fund, Hatteras Venture Partners, Bristol-Myers Squibb.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for GeneCentric
- ·The full record, as it builds
Funding rounds
No funding rounds for GeneCentric are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GeneCentric
Developer of a molecular diagnostic platform designed to characterize tumor biology in a manner that facilitates optimal targeting of therapeutic compounds. The company's platform engages in developing tests that identify patients who would benefit from drugs that inhibit tumor growth, enabling clinicians to make a rational clinical trial design, efficient target selection in drug development and improved treatment outcomes.
- Sector
- Healthcare
- HQ
- NC
- Founded
- 2011
- Employees
- 12
- Website
- genecentric.com/
- Ownership
- Privately Held (backing)
GeneCentric doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GeneCentric shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GeneCentric in its N-PORT filings yet. We sweep new filings monthly.